A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura (Complement C5 Inhibitor) Compared to Sham in Subjects With Autosomal Recessive Stargardt Disease

Trial Profile

A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura (Complement C5 Inhibitor) Compared to Sham in Subjects With Autosomal Recessive Stargardt Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2018

At a glance

  • Drugs Avacincaptad pegol (Primary)
  • Indications Stargardt disease
  • Focus Therapeutic Use
  • Sponsors OphthoTech Corporation
  • Most Recent Events

    • 01 Aug 2018 According to an OphthoTech Corporation media release, initial top-line data expected to be available in 2020.
    • 09 May 2018 According to an OphthoTech Corporation media release, the scientific details of this clinical trial were presented at the 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) and at the International Symposium on Ocular Pharmacology and Therapeutics.
    • 27 Feb 2018 According to an OphthoTech Corporation media release, the scientific details of this clinical trial will be presented at The International Symposium on Ocular Pharmacology and Therapeutics in Tel-Aviv, Israel.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top